Excellos launches to advance cell and gene therapies
Excellos, a cell therapy contract development and manufacturing organization, has announced its official corporate launch and closing of $15 million in funding from Telegraph Hill Partners. Read More
Samsung Biologics reports Q4, 2021 fiscal year financial results
Samsung Biologics reported strong financial results for the fourth quarter and record high earnings for the 2021 fiscal year, achieving fourth quarter revenue of 444.3 billion South Korean won ($37 million U.S.), an increase of 18% from 375.3 billion South Korean won ($31 billion U.S.) reported for the fourth quarter last year. Read More
Illumina collaborates with National Cancer Center Japan
Illumina and National Cancer Center Japan are collaborating on an international joint research project that will use Illumina's high-throughput DNA sequencing to analyze the blood-based genomic profile and clinical information of patients living with nasopharyngeal carcinoma. Read More
Harbour BioMed successfully doses antiCTLA-4 antibody
Harbour BioMed has successfully completed dosing of the first patient in a phase IB/IIA trial at the stage of dose expansion of its anticytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody, HBM4003, in combination therapy with toripalimab, an antiprogrammed cell death protein 1 antibody, for patients suffering from advanced melanoma and solid tumors. Read More
Anixa Biosciences, MolGenie announce SARS-CoV-2 protease inhibitor
Anixa Biosciences and its partner MolGenie have synthesized a compound that appears to be considerably more potent than nirmatrelvir at inhibiting the main protease of the SARS-CoV-2 virus. Read More
NanoMosaic signs lease for multiomics HQ in Waltham, Mass.
NanoMosaic has signed a lease for a stand-alone building of 30,880 sq ft in Waltham, MA. NanoMosaic is a biotechnology company that pioneered nanoneedle (MosaicNeedle) technology detection for proteomics, genomics, and single-run experiment multiomics applications, alongside the development of assays for biomarker discovery and validation. Read More
BenchSci raises $63M Canadian dollars to expand AI-powered software platform
BenchSci, a developer of machine-learning applications for novel medicine development, has obtained $63 million Canadian dollars ($50 million) through a series C funding round. The funding will allow the company to expedite the expansion of its artificial intelligence (AI)-powered software platform. Read More
FDA expands use of remdesivir to outpatients with mild-to-moderate COVID-19
The U.S. Food and Drug Administration (FDA) has expanded the use of the antiviral drug Veklury (remdesivir) to certain nonhospitalized adults and pediatric patients for the treatment of mild-to-moderate COVID-19 disease. Read More
SQZ Biotechnologies receives FDA clearance of IND for cancer cell therapy
SQZ Biotechnologies announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for SQZ-eAPC-HPV, authorizing the company to proceed with initiating a phase I/II clinical trial of the novel cell therapy candidate. Read More
10x Genomics adds global CROs
10x Genomics has expanded its 10x Certified Service Provider network to include three leading clinical research organizations (CROs). The organizations will partner with 10x Genomics to support global biopharmaceutical companies seeking to leverage 10x Genomics' single-cell and spatial technologies to power new therapeutic discoveries and accelerate drug development. Read More
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
